New Zealanders for Health Research

Clinical Trials Workshop

Description

Clinical trials provide many benefits to New Zealand, including economic benefits from international investment, avoided costs in the public healthcare system, improved health outcomes and individual patient benefits in the case of some trials. 

However, there is potential to significantly boost the current level of activity. The purpose of the workshop will be to develop recommendations from a cross section of stakeholders on interventions required to increase DHB involvement, support offshore investment and promote New Zealanders’ participation in clinical trials.

This workshop is open to anyone with an interest in contributing to both better health outcomes and the country’s economy by growing New Zealand’s clinical trials sector. Workshop participants will be actively involved in discussing three key areas where changes in policy settings or other interventions could deliver significant benefits for the clinical trials sector in New Zealand.

If you’d like to be part of making a difference in a sector which contributes both to New Zealanders’ health outcomes and the country’s economy, register via the link above.

Registration will be on a first come first service and will be limited to a maximum of fifty participants.

Who should attend?

Representatives from pharmaceutical companies, CROs, private clinical trial sites in New Zealand, DHBs, Ministry of Health, funders of clinical trials, and patient advocacy groups.  

Cost

Employees of bronze member organisations are entitled to one, gold members up to three, and platinum members up to five complementary registrations.

The cost for all others is $100.00+GST per participant.

Please see below for member organisation details.

Format

The format of the workshop will involve short presentations to provide a reference point for discussion.  Participants at the workshop will provide a broad range of perspectives and the focus of the day is to build a consensus on what actions are required for New Zealand to maximize the economic and health benefits of its clinical trials sector. 

This consensus will then be conveyed to government and Ministry policy makers and will also form part of New Zealanders for Health Research’s workplan for 2017/18.

Programme

9.30 – 10.00  Morning coffee and networking

10.00 – 10.30  Welcome and opening comments

10.30 – 12.00  Increasing DHB involvement in clinical trials

This session will identify strategies for increasing DHB involvement in clinical trials in order. This was an issue which was the subject of recommendations from the 2011 Health Select Committee’s clinical trials review, and where follow up action may have faltered. There are important public health benefits for New Zealanders and New Zealand DHBs from being involved in clinical trials, and there can also be savings to DHBs as a result of treatment and service costs being covered by the trial sponsors.

12.00 – 12.30  Lunch

12.30 – 1.45  Maximising the commercial benefits of participating in clinical trials

New Zealand benefits when sponsors come here and spend money on trials. However, we operate in a global marketplace, and New Zealand has no innate advantage over any other country.  We have an advanced health system so participants from New Zealand meet FDA requirements for first-world participants trials, but we are competing against some very slick offerings from other countries.  Korea has an excellent reputation for trial delivery, and Australia has a 40% tax rebate.  New Zealand offers no incentives, and as a result we risk losing ground against other countries and therefore losing investment.

This session therefore will identify strategies for incentivising industry investment in clinical trials, thereby increasing our competitiveness in the global market place

1.45 – 3.00  Clinical trials recruitment

This session will identify strategies for promoting and removing barriers to clinical trials recruitment. Discussion topics will include consenting processes and requirements, ACC coverage for clinical trials participants who experience treatment injury, and development of systemic approaches to proactively increasing the pool of potential participants

3.00 – 3.30

Concluding comments including confirmation of follow up actions.

Our supporters

Platinum      

 

Gold         

 

Bronze               

 

Other